Shanghai Xinshi Biomedical Co., Ltd.

Primary study objectives: ￣ Evaluate the safety and tolerability of NBL-028 in subjects with advanced solid tumors ￣ Determine the maximum tolerated dose (MTD) (if any), subsequent recommended doses and dosing regimens of NBL-028 Secondary study objectives: ￣ Evaluate the pharmacokinetic (PK) characteristics of NBL-028 in subjects with advanced solid tumors ￣ Evaluate the preliminary anti-tumor activity of NBL-028 in subjects with advanced solid tumors ￣ Evaluate the immunogenicity of NBL-028 in subjects with advanced solid tumors

Main purpose: To evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) (if any), recommended dose for Phase II (RP2D) and dosing regimen of NBL-020. Secondary purpose: 1) To evaluate the pharmacokinetic (PK) characteristics of NBL-020 injection in subjects with advanced malignant tumors. 2) To evaluate the preliminary anti-tumor activity of NBL-020 injection in subjects with advanced malignant tumors. 3) To evaluate the immunogenicity of NBL-020 injection in subjects with advanced malignant tumors. 4) To evaluate the pharmacodynamic (PD) indicators of NBL-020 injection.

Primary objective: To evaluate the safety and tolerability of a single subcutaneous injection of NBL-012 in healthy Chinese subjects. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous injection of NBL-012 in healthy Chinese subjects. 2. To evaluate the immunogenicity of a single subcutaneous injection of NBL-012 in healthy Chinese subjects. 3. To evaluate the pharmacodynamic (PD) characteristics of a single subcutaneous injection of NBL-012 in healthy Chinese subjects.